RadNet, Inc. (NASDAQ:RDNT) Shares Bought by Harvest Investment Services LLC

Harvest Investment Services LLC boosted its holdings in RadNet, Inc. (NASDAQ:RDNT - Free Report) by 94.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,522 shares of the medical research company's stock after purchasing an additional 14,327 shares during the quarter. Harvest Investment Services LLC's holdings in RadNet were worth $2,062,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. USA Financial Formulas bought a new position in RadNet during the fourth quarter valued at approximately $30,000. Fifth Third Bancorp grew its stake in shares of RadNet by 84.3% in the 4th quarter. Fifth Third Bancorp now owns 667 shares of the medical research company's stock worth $47,000 after buying an additional 305 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of RadNet by 377.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,345 shares of the medical research company's stock worth $96,000 after buying an additional 1,063 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of RadNet by 42.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,422 shares of the medical research company's stock worth $99,000 after buying an additional 422 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of RadNet during the 4th quarter valued at about $105,000. 77.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Cornelis Wesdorp sold 1,000 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $50.52, for a total value of $50,520.00. Following the completion of the sale, the chief executive officer now owns 55,995 shares of the company's stock, valued at approximately $2,828,867.40. This represents a 1.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David L. Swartz sold 25,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $50.84, for a total transaction of $1,271,000.00. Following the completion of the transaction, the director now directly owns 174,067 shares of the company's stock, valued at $8,849,566.28. This trade represents a 12.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,000 shares of company stock valued at $1,926,730 over the last quarter. 5.12% of the stock is owned by corporate insiders.

RadNet Trading Down 0.4 %

Shares of NASDAQ:RDNT traded down $0.19 on Friday, hitting $50.26. 581,287 shares of the company's stock were exchanged, compared to its average volume of 664,913. The stock has a market capitalization of $3.72 billion, a price-to-earnings ratio of -717.90 and a beta of 1.59. RadNet, Inc. has a 12 month low of $45.00 and a 12 month high of $93.65. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.16 and a quick ratio of 2.16. The business's 50 day simple moving average is $51.71 and its two-hundred day simple moving average is $64.42.

RadNet (NASDAQ:RDNT - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.21 by $0.01. The company had revenue of $477.10 million for the quarter, compared to the consensus estimate of $459.42 million. RadNet had a negative net margin of 0.25% and a positive return on equity of 4.29%. Analysts anticipate that RadNet, Inc. will post 0.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Jefferies Financial Group dropped their price target on RadNet from $100.00 to $80.00 and set a "buy" rating for the company in a research report on Wednesday, January 15th. StockNews.com raised RadNet to a "sell" rating in a research report on Wednesday, March 19th. Raymond James upgraded RadNet from an "outperform" rating to a "strong-buy" rating and decreased their price target for the company from $85.00 to $65.00 in a report on Wednesday, March 5th. Barclays cut their price objective on shares of RadNet from $74.00 to $60.00 and set an "overweight" rating on the stock in a research report on Monday, March 24th. Finally, Truist Financial dropped their price target on shares of RadNet from $88.00 to $74.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $69.75.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.